Back to search

Article

Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib

2023-10-27

Abstract excerpt

Dacomitinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and EGFR-activating mutations. Proton pump inhibitors decreased dacomitinib exposure. This anal-ysis summarizes the effect of H2RA on dacomitinib exposure. A within-patient comparison of steady-state trough concentrations (Ctrough,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bb43d80d-576c-5359-ba20-3f2805f93475
DOI
10.20944/preprints202310.1726.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effects of H2-Receptor Antagonists on the Exposure of DacomitinibDOI 10.20944/preprints202310.1726.v1
[A review: drug-drug interactions of epithelial growth factor receptor-tyrosine kinase inhibitors].Semantic proximity
Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6.Semantic proximity
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.Semantic proximity
Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.Semantic proximity
Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer.Semantic proximity
Pharmacokinetics of crizotinib in NSCLC patients.Semantic proximity
Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).Semantic proximity
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.Semantic proximity
Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.Semantic proximity
Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.Semantic proximity
Development and validation of an LC-MS/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics.Semantic proximity
Select a neighboring publication to make it the new centre.